PBLS
Parabilis achieves 72.2% ORR for zolucatetide in desmoid tumors
Parabilis reported updated Phase 1/2 data showing strong efficacy in desmoid tumors and secured FDA alignment for its upcoming Phase 3 trial. With $1.1 billion in cash, the company expects to fund operations through 2030.